Skip to main content
PMC home page
Gut logoLink to Gut
. 1997 Jul;41(1):107–114. doi: 10.1136/gut.41.1.107

Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE).

G Cadiot 1, G Bonnaud 1, R Lebtahi 1, L Sarda 1, P Ruszniewski 1, D Le Guludec 1, M Mignon 1
PMCID: PMC1027237  PMID: 9274481

Abstract

BACKGROUND: Management of patients with Zollinger-Ellison syndrome (ZES) depends on the presence of multiple endocrine neoplasia type 1 (MEN 1) or liver metastases, or both. Somatostatin receptor scintigraphy (SRS) detects previously unknown endocrine tumours. AIM AND METHODS: To evaluate SRS findings susceptible to modifying the management of patients with ZES-that is, relevant findings, and the specificity of these findings. The latter were defined according to our current therapeutic strategy in three subgroups of patients (sporadic, MEN 1, and liver metastases). PATIENTS: 85 consecutive patients without known extra-abdominal metastases were studied between September 1991 and March 1996. RESULTS: Relevant findings were found in 41% of 49 patients with sporadic disease but without liver metastases, in 22% of 18 patients with MEN 1 but without liver metastases, and in 17% of 18 patients with liver metastases. Follow up was available for 20 (74%) of 27 patients who had 23 relevant findings. Nineteen relevant findings (83%) were confirmed at a median of three (range 0.25-45) months of follow up; four (17%) were not confirmed at 30 (range 12-52) months (p = 0.025). Findings located in the duodenopancreatic area (90%), chest (100%), bone (100%), and liver (60%) were confirmed. Most findings for patients with MEN 1 involved the chest. CONCLUSION: SRS detects many anomalies susceptible to modifying management of patients with ZES, especially in those with sporadic disease. The specificity of hot spots located outside the liver seems very high. By contrast, the specificity of hot spots located in the liver remains to be evaluated when conventional imaging is negative.

Full text

PDF
107

Images in this article

112Image
on p.112
112Image
on p.112

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berger J. F., Laissy J. P., Limot O., Henry-Feugeas M. C., Cadiot G., Mignon M., Schouman-Claeys E. Differentiation between multiple liver hemangiomas and liver metastases of gastrinomas: value of enhanced MRI. J Comput Assist Tomogr. 1996 May-Jun;20(3):349–355. doi: 10.1097/00004728-199605000-00003. [DOI] [PubMed] [Google Scholar]
  2. Cadiot G., Houillier P., Allouch A., Paillard M., Mignon M. Oral calcium tolerance test in the early diagnosis of primary hyperparathyroidism and multiple endocrine neoplasia type 1 in patients with the Zollinger-Ellison syndrome. Groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison. Gut. 1996 Aug;39(2):273–278. doi: 10.1136/gut.39.2.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cadiot G., Lebtahi R., Sarda L., Bonnaud G., Marmuse J. P., Vissuzaine C., Ruszniewski P., Le Guludec D., Mignon M. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe D'etude Du Syndrome De Zollinger-Ellison. Gastroenterology. 1996 Oct;111(4):845–854. doi: 10.1016/s0016-5085(96)70052-5. [DOI] [PubMed] [Google Scholar]
  4. Donow C., Pipeleers-Marichal M., Schröder S., Stamm B., Heitz P. U., Klöppel G. Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy. Cancer. 1991 Sep 15;68(6):1329–1334. doi: 10.1002/1097-0142(19910915)68:6<1329::aid-cncr2820680624>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  5. Ellison E. C. Forty-year appraisal of gastrinoma. Back to the future. Ann Surg. 1995 Oct;222(4):511–524. doi: 10.1097/00000658-199522240-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gibril F., Reynolds J. C., Doppman J. L., Chen C. C., Venzon D. J., Termanini B., Weber H. C., Stewart C. A., Jensen R. T. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med. 1996 Jul 1;125(1):26–34. doi: 10.7326/0003-4819-125-1-199607010-00005. [DOI] [PubMed] [Google Scholar]
  7. Jamar F., Fiasse R., Leners N., Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med. 1995 Apr;36(4):542–549. [PubMed] [Google Scholar]
  8. Krenning E. P., Kwekkeboom D. J., Oei H. Y., de Jong R. J., Dop F. J., de Herder W. W., Reubi J. C., Lamberts S. W. Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome. Digestion. 1994;55 (Suppl 3):54–59. doi: 10.1159/000201202. [DOI] [PubMed] [Google Scholar]
  9. MacFarlane M. P., Fraker D. L., Alexander H. R., Norton J. A., Lubensky I., Jensen R. T. Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. Surgery. 1995 Dec;118(6):973–980. doi: 10.1016/s0039-6060(05)80102-3. [DOI] [PubMed] [Google Scholar]
  10. Melvin W. S., Johnson J. A., Sparks J., Innes J. T., Ellison E. C. Long-term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia. Surgery. 1993 Dec;114(6):1183–1188. [PubMed] [Google Scholar]
  11. Mignon M., Bonfils S. Diagnosis and treatment of Zollinger-Ellison syndrome. Baillieres Clin Gastroenterol. 1988 Jul;2(3):677–698. doi: 10.1016/s0950-3528(88)80013-7. [DOI] [PubMed] [Google Scholar]
  12. Mignon M., Ruszniewski P., Podevin P., Sabbagh L., Cadiot G., Rigaud D., Bonfils S. Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type I. World J Surg. 1993 Jul-Aug;17(4):489–497. doi: 10.1007/BF01655108. [DOI] [PubMed] [Google Scholar]
  13. Norton J. A., Doppman J. L., Jensen R. T. Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study. Ann Surg. 1992 Jan;215(1):8–18. doi: 10.1097/00000658-199201000-00012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Norton J. A., Jensen R. T. Unresolved surgical issues in the management of patients with Zollinger-Ellison syndrome. World J Surg. 1991 Jan-Feb;15(1):151–159. doi: 10.1007/BF01658992. [DOI] [PubMed] [Google Scholar]
  15. Reubi J. C. Clinical relevance of somatostatin receptor imaging. Eur J Endocrinol. 1994 Dec;131(6):575–576. doi: 10.1530/eje.0.1310575. [DOI] [PubMed] [Google Scholar]
  16. Ruszniewski P., Podevin P., Cadiot G., Marmuse J. P., Mignon M., Vissuzaine C., Bonfils S., Lehy T. Clinical, anatomical, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type I multiple endocrine neoplasia. Pancreas. 1993 May;8(3):295–304. doi: 10.1097/00006676-199305000-00003. [DOI] [PubMed] [Google Scholar]
  17. Schirmer W. J., Melvin W. S., Rush R. M., O'Dorisio T. M., Pozderac R. V., Olsen J. O., Ellison E. C. Indium-111-pentetreotide scanning versus conventional imaging techniques for the localization of gastrinoma. Surgery. 1995 Dec;118(6):1105–1114. doi: 10.1016/s0039-6060(05)80121-7. [DOI] [PubMed] [Google Scholar]
  18. Sugg S. L., Norton J. A., Fraker D. L., Metz D. C., Pisegna J. R., Fishbeyn V., Benya R. V., Shawker T. H., Doppman J. L., Jensen R. T. A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg. 1993 Aug;218(2):138–144. doi: 10.1097/00000658-199308000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Thompson N. W. The surgical management of hyperparathyroidism and endocrine disease of the pancreas in the multiple endocrine neoplasia type 1 patient. J Intern Med. 1995 Sep;238(3):269–280. doi: 10.1111/j.1365-2796.1995.tb00934.x. [DOI] [PubMed] [Google Scholar]
  20. Weber H. C., Venzon D. J., Lin J. T., Fishbein V. A., Orbuch M., Strader D. B., Gibril F., Metz D. C., Fraker D. L., Norton J. A. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology. 1995 Jun;108(6):1637–1649. doi: 10.1016/0016-5085(95)90124-8. [DOI] [PubMed] [Google Scholar]
  21. Zimmer T., Stölzel U., Bäder M., Koppenhagen K., Hamm B., Buhr H., Riecken E. O., Wiedenmann B. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut. 1996 Oct;39(4):562–568. doi: 10.1136/gut.39.4.562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. de Kerviler E., Cadiot G., Lebtahi R., Faraggi M., Le Guludec D., Mignon M. Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. GRESZE: Groupe d'Etude du Syndrome de Zollinger-Ellison. Eur J Nucl Med. 1994 Nov;21(11):1191–1197. doi: 10.1007/BF00182352. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES